Onconic Therapeutics Inc. (KOSDAQ:476060)

South Korea flag South Korea · Delayed Price · Currency is KRW
16,370
-140 (-0.85%)
Dec 10, 2025, 3:30 PM KST
Market Cap734.53B
Revenue (ttm)46.65B
Net Income (ttm)16.75B
Shares Out44.49M
EPS (ttm)1,513.84
PE Ratio10.91
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,043,710
Average Volume5,032,330
Open16,400
Previous Close16,510
Day's Range15,930 - 16,710
52-Week Range3,138 - 26,600
Betan/a
RSI45.99
Earnings DateNov 11, 2025

About Onconic Therapeutics

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476060
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.